NEW YORK--(BUSINESS WIRE)--March 15, 2001
International pharmaceutical and healthcare company, F H Faulding & Co Limited (Faulding) today announced that its Faulding Pharmaceuticals division has received FDA approval for additional dosage strengths of Kadian(R) brand sustained-release morphine sulphate product in the USA.
Kadian competes in the sustained-release opioid market, valued at US$1.8 billion in the USA and growing at more than 60 per cent per annum. Kadian has been marketed in the USA by Faulding Laboratories, the Company's branded pharmaceuticals business, since early 1998. Prescriptions of Kadian have grown by 180 per cent over the past year.
Mr Frank Condella, President & Chief Executive Officer of Faulding Pharmaceuticals, said: "Kadian is positioned as the preferred oral sustained-release opioid due to the flexibility it offers in treating patients with moderate to severe chronic pain. It is the only sustained-release morphine sulphate product to be approved for once-daily administration, but may also be taken twice daily by patients preferring a more frequent dosage schedule. Kadian offers unique flexibility in administration, including sprinkle and gastronomy tube administration. The approval of the 30mg and 60mg capsules now provides patients with an expanded range of dosage options, further optimising the flexibility offered by Kadian."
Faulding is a worldwide health and personal care company, listed on the Australian Stock Exchange. Faulding's principal businesses are oral and injectable pharmaceuticals, consumer health products, the provision of distribution and retail management services to pharmacies and logistics management services to hospitals. Faulding products are sold in over 70 countries.
KADIAN is a registered trade mark of F H Faulding & Co Limited.
COPYRIGHT 2001 Business Wire
COPYRIGHT 2001 Gale Group